Skip to main content

Table 4 Mean percent blood glucose reduction in normal rats (N = 6)

From: Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models

Time

(h)

Gliclazide

Nevirapine

Nevirapine + Gliclazide*(Single dose treatment)

Nevirapine + Gliclazide*(Multiple dose treatment)

1

30.88 ± 1.12

-01.44 ± 0.46

30.43 ± 1.09

30.83 ± 0.94

2

40.72 ± 0.56

02.88 ± 0.45

38.35 ± 0.72

40.49 ± 0.84

3

28.34 ± 0.82

03.96 ± 0.64

26.84 ± 0.79

28.30 ± 0.68

4

23.97 ± 0.79

04.68 ± 0.65

22.90 ± 0.99

23.63 ± 1.13

6

30.90 ± 0.46

02.51 ± 0.66

30.42 ± 1.00

31.53 ± 0.67

8

37.46 ± 1.18

01.43 ± 0.71

35.14 ± 1.23

37.62 ± 1.44

10

24.73 ± 0.69

01.05 ± 1.66

23.61 ± 1.01

25.81 ± 0.76

12

10.52 ± 1.14

00.34 ± 1.40

10.33 ± 1.30

11.80 ± 1.16

  1. *Statistically no significance compared to gliclazide control